Tech Company Financing Transactions
Replimune Funding Round
Replimune closed a $30 million Series A investment round on 9/25/2015. Investors included Atlas Accelerator, Forbion Capital Partners and Omega Funds.
Transaction Overview
Company Name
Announced On
9/25/2015
Transaction Type
Venture Equity
Amount
$30,000,000
Round
Series A
Investors
Proceeds Purpose
The company intends to progress these immunotherapies through clinical trials and to combine them with checkpoint blockade at an early stage of clinical development.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
500 Unicorn Park Dr. 3rd Floor
Woburn, MA 01801
USA
Woburn, MA 01801
USA
Phone
Website
Email Address
Overview
Oncolytic immunotherapy is an emerging class of cancer therapeutics which exploit the ability of viruses to selectively replicate in and kill tumor tissue, while at the same time inducing a potent, patient-specific, anti-tumor immune response.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chairman
Philip Sparke
Chief Executive Officer
Robert Coffin
Chief Operating Officer
Colin Love
VP - Bus. Development
Pamela Esposito
Browse more venture capital transactions:
Prev: 9/25/2015: Retrieve Technologies venture capital transaction
Next: 9/25/2015: StreamSets venture capital transaction
Share this article
About Database of VC Transactions
We do our best to document every notable VC transaction. VC transactions reported here are derived from company press releases and news coverage. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs